首页 > 最新文献

Turkderm-Archives of the Turkish Dermatology and Venerology最新文献

英文 中文
Factors contributing to activity limitations in Leprosy patients in Sitanala Leprosy Village, Indonesia 印度尼西亚Sitanala麻风村麻风患者活动受限的因素
Q4 Medicine Pub Date : 2022-09-30 DOI: 10.4274/turkderm.galenos.2022.99835
Anandika Pawitri, S. Menaldi, M. Marissa
Background and Design: To investigate the association between sociodemographic variables, illness duration, leprosy types, comorbidities, and World Health Organization disability grading system for leprosy with daily activity limitations in people with leprosy who had completed multidrug therapy. Materials and Methods: A cross-sectional study was conducted in Sitanala Leprosy Village, Tangerang, Indonesia, in April 2018. Sociodemographic data and leprosy baseline characteristics were obtained from patients with leprosy who had completed multidrug therapy. The Screening of Activity Limitation and Safety Awareness scale was used to measure limitations in performing daily functional activities. Results: A total of 205 people were included in the study, of which 39 (19%) had eye disabilities, 178 (86.8%) had hand disabilities, and 187 (91.2%) had foot disabilities. A total of 135 (65.8%) people had mild-to-moderate functional limitation, and 33 (16%) had severe-to-very severe functional limitation. The proportion of unemployed individuals was higher among those with severe-extreme limitation compared to those without significant limitation (p=0.01). Individuals with eye disability had a higher risk of having severe-extreme activity limitation compared to those without eye disability (p=0.008). A dose-response association of hands and foot disabilities with activity limitation was found; the adjusted odds ratio (OR) of the association of hands and foot disabilities with mild-moderate activity limitation was 3.03 (p=0.012), and the association was greater with severe-extreme activity limitation (adjusted OR; 20.38, p=0.006). Conclusion: Severe disability is associated with functional activity limitations. The findings of the present study can guide healthcare providers in designing appropriate prevention and intervention services for patients with leprosy-related disabilities.
背景与设计:研究完成多药治疗的麻风病患者每日活动受限麻风病的社会人口学变量、病程、麻风病类型、合并症和世界卫生组织残疾分级系统之间的关系。材料与方法:于2018年4月在印度尼西亚Tangerang的Sitanala麻风病村进行了一项横断面研究。从完成多药治疗的麻风病患者中获得社会人口学数据和麻风病基线特征。活动限制筛选和安全意识量表用于测量日常功能活动的限制。结果:共纳入205人,其中眼残39人(19%),手残178人(86.8%),足残187人(91.2%)。共有135人(65.8%)有轻度至中度功能限制,33人(16%)有严重至非常严重的功能限制。严重-极端限制组的失业人口比例高于无显著限制组(p=0.01)。与没有眼残疾的人相比,有眼残疾的人发生严重极端活动限制的风险更高(p=0.008)。发现手脚残疾与活动受限存在剂量-反应关联;手足残疾与轻中度活动受限相关的校正比值比(OR)为3.03 (p=0.012),与重度-极端活动受限相关的校正比值比(OR;20.38, p = 0.006)。结论:重度残疾与功能活动受限有关。本研究结果可指导卫生保健提供者为麻风相关残疾患者设计适当的预防和干预服务。
{"title":"Factors contributing to activity limitations in Leprosy patients in Sitanala Leprosy Village, Indonesia","authors":"Anandika Pawitri, S. Menaldi, M. Marissa","doi":"10.4274/turkderm.galenos.2022.99835","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2022.99835","url":null,"abstract":"Background and Design: To investigate the association between sociodemographic variables, illness duration, leprosy types, comorbidities, and World Health Organization disability grading system for leprosy with daily activity limitations in people with leprosy who had completed multidrug therapy. Materials and Methods: A cross-sectional study was conducted in Sitanala Leprosy Village, Tangerang, Indonesia, in April 2018. Sociodemographic data and leprosy baseline characteristics were obtained from patients with leprosy who had completed multidrug therapy. The Screening of Activity Limitation and Safety Awareness scale was used to measure limitations in performing daily functional activities. Results: A total of 205 people were included in the study, of which 39 (19%) had eye disabilities, 178 (86.8%) had hand disabilities, and 187 (91.2%) had foot disabilities. A total of 135 (65.8%) people had mild-to-moderate functional limitation, and 33 (16%) had severe-to-very severe functional limitation. The proportion of unemployed individuals was higher among those with severe-extreme limitation compared to those without significant limitation (p=0.01). Individuals with eye disability had a higher risk of having severe-extreme activity limitation compared to those without eye disability (p=0.008). A dose-response association of hands and foot disabilities with activity limitation was found; the adjusted odds ratio (OR) of the association of hands and foot disabilities with mild-moderate activity limitation was 3.03 (p=0.012), and the association was greater with severe-extreme activity limitation (adjusted OR; 20.38, p=0.006). Conclusion: Severe disability is associated with functional activity limitations. The findings of the present study can guide healthcare providers in designing appropriate prevention and intervention services for patients with leprosy-related disabilities.","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44713042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cutis marmorata telangiectatica congenita on hand and forearm: Initial and follow-up observations of a rare case 先天性手部和前臂上的唇腭裂毛细血管扩张症:一例罕见病例的初步和随访观察
Q4 Medicine Pub Date : 2022-09-30 DOI: 10.4274/turkderm.galenos.2022.98957
C. B. Türk, Dilara Ilhan, Ozan Erdem, M. Gürel, A. E. Koku Aksu
{"title":"Cutis marmorata telangiectatica congenita on hand and forearm: Initial and follow-up observations of a rare case","authors":"C. B. Türk, Dilara Ilhan, Ozan Erdem, M. Gürel, A. E. Koku Aksu","doi":"10.4274/turkderm.galenos.2022.98957","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2022.98957","url":null,"abstract":"","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45410214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What is your diagnosis? 你的诊断是什么?
Q4 Medicine Pub Date : 2022-09-30 DOI: 10.4274/turkderm.galenos.2022.01460
Gülistan Maçin
{"title":"What is your diagnosis?","authors":"Gülistan Maçin","doi":"10.4274/turkderm.galenos.2022.01460","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2022.01460","url":null,"abstract":"","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47737670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serum vitamin B12, ferritin, and vitamin D levels in patients with seborrheic dermatitis: A case-control study 脂溢性皮炎患者血清维生素B12、铁蛋白和维生素D水平:一项病例对照研究
Q4 Medicine Pub Date : 2022-09-30 DOI: 10.4274/turkderm.galenos.2022.30776
Semih Güder, Hüsna Güder
{"title":"Serum vitamin B12, ferritin, and vitamin D levels in patients with seborrheic dermatitis: A case-control study","authors":"Semih Güder, Hüsna Güder","doi":"10.4274/turkderm.galenos.2022.30776","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2022.30776","url":null,"abstract":"","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46196164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between Localized Scleroderma Cutaneous Assessment Tool and clinicopathologic characteristics in patients with morphea 局限性硬皮病皮肤评估工具与变形患者临床病理特征的相关性
Q4 Medicine Pub Date : 2022-09-30 DOI: 10.4274/turkderm.galenos.2022.07347
Y. Gürsel Ürün, E. Usturalı Keskin
Background and Design: Morphea is also known as localized scleroderma. It is a rare autoimmune skin disease characterized by inflammation and sclerosis in the dermis and sometimes in the subcutaneous tissue. Laboratory findings, imaging, and histopathological features facilitate diagnosis and provide sufficient information about disease severity. Clinicopathologic correlations and severity factors in morphea are poorly described. Thus, this study aimed to review the clinical and histopathological features and treatment responses of patients with morphea and compare these features with disease activity and damage scores to identify new tools for assessing disease severity other than clinical findings. The applicability of the Localized Scleroderma Cutaneous Assessment Tool in clinical practice was also evaluated. Materials and Methods: This study reviewed data of 41 patients who had a histopathologically confirmed diagnosis of morphea and had been followed up regularly for at least 6 months. The modified Localized Scleroderma Skin Severity Index (mLoSSI), Localized Scleroderma Skin Damage Index (LoSDI), Physician Global Assessment-Activity (PGA-A), and Physician Global Assessment-Damage (PGA-D) were calculated at baseline and final treatment. Results: Among morphea subtypes, superficial morphea had significantly more sclerosis in the papillary dermis and plaque-type morphea had significantly more sclerosis in the reticular dermis (p<0.05). When positive antinuclear antibody (ANA) and high levels of thyroid autoantibodies were compared with mLoSSI, LoSDI, PGA-A, and PGA-D scores at baseline, no significant correlation was found. Comparison of the subgroups according to the initial mLoSSI and LoSDI scores revealed no significant histopathological differences between the groups. Conclusion: Although the mLoSSI, LoSDI, PGA-A, and PGA-D scores can be successfully used for the follow-up and treatment of patients with morphea, no correlation was found between positive ANA, high levels of thyroid autoantibodies, and histopathological features. autoimmune diseases, clinical symptoms, and concomitant lichen sclerosus et atrophicus (LSA) were recorded. Laboratory results, detailed treatment modalities, treatment duration, and treatment responses were assessed. The same dermatologist performed a biopsy of the erythematous rim of the inflammatory lesions or central sclerosis of the lesions that did not clinically show inflammation using a 4 mm punch biopsy instrument. Incisional biopsy was performed in patients with a provisional diagnosis of linear morphea, deep type morphea, or eosinophilic fasciitis.
背景与设计:多发性硬皮病又称局部硬皮病。这是一种罕见的自身免疫性皮肤病,其特征是真皮层炎症和硬化症,有时在皮下组织。实验室检查、影像学和组织病理学特征有助于诊断,并提供有关疾病严重程度的充分信息。morphea的临床病理相关性和严重程度因素描述甚少。因此,本研究旨在回顾morphea患者的临床和组织病理学特征和治疗反应,并将这些特征与疾病活动性和损伤评分进行比较,以确定除临床表现外评估疾病严重程度的新工具。并对局限性硬皮病皮肤评估工具在临床实践中的适用性进行了评价。材料和方法:本研究回顾了41例经组织病理学确诊为睡眠不足的患者的资料,并定期随访至少6个月。在基线和最终治疗时计算改良的局部硬皮病皮肤严重程度指数(mLoSSI)、局部硬皮病皮肤损伤指数(LoSDI)、医生整体评估-活动(PGA-A)和医生整体评估-损伤(PGA-D)。结果:在morphea亚型中,浅表性morphea明显多于乳头状真皮硬化,斑块型morphea明显多于网状真皮硬化(p<0.05)。当抗核抗体(ANA)阳性和高水平甲状腺自身抗体与基线时的mLoSSI、LoSDI、PGA-A和PGA-D评分进行比较时,未发现显著相关性。根据初始mLoSSI和LoSDI评分对亚组进行比较,结果显示各组之间没有明显的组织病理学差异。结论:虽然mLoSSI、LoSDI、PGA-A、PGA-D评分可以成功用于吗啡患者的随访和治疗,但ANA阳性、甲状腺自身抗体水平高与组织病理学特征之间没有相关性。记录自身免疫性疾病、临床症状和伴随的硬化性萎缩性地衣(LSA)。评估了实验室结果、详细的治疗方式、治疗时间和治疗反应。同一位皮肤科医生使用4毫米穿孔活检仪对炎性病变的红斑边缘或没有临床炎症表现的病变的中央硬化进行活检。对暂时诊断为线状脑膜瘤、深部脑膜瘤或嗜酸性筋膜炎的患者进行切口活检。
{"title":"Association between Localized Scleroderma Cutaneous Assessment Tool and clinicopathologic characteristics in patients with morphea","authors":"Y. Gürsel Ürün, E. Usturalı Keskin","doi":"10.4274/turkderm.galenos.2022.07347","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2022.07347","url":null,"abstract":"Background and Design: Morphea is also known as localized scleroderma. It is a rare autoimmune skin disease characterized by inflammation and sclerosis in the dermis and sometimes in the subcutaneous tissue. Laboratory findings, imaging, and histopathological features facilitate diagnosis and provide sufficient information about disease severity. Clinicopathologic correlations and severity factors in morphea are poorly described. Thus, this study aimed to review the clinical and histopathological features and treatment responses of patients with morphea and compare these features with disease activity and damage scores to identify new tools for assessing disease severity other than clinical findings. The applicability of the Localized Scleroderma Cutaneous Assessment Tool in clinical practice was also evaluated. Materials and Methods: This study reviewed data of 41 patients who had a histopathologically confirmed diagnosis of morphea and had been followed up regularly for at least 6 months. The modified Localized Scleroderma Skin Severity Index (mLoSSI), Localized Scleroderma Skin Damage Index (LoSDI), Physician Global Assessment-Activity (PGA-A), and Physician Global Assessment-Damage (PGA-D) were calculated at baseline and final treatment. Results: Among morphea subtypes, superficial morphea had significantly more sclerosis in the papillary dermis and plaque-type morphea had significantly more sclerosis in the reticular dermis (p<0.05). When positive antinuclear antibody (ANA) and high levels of thyroid autoantibodies were compared with mLoSSI, LoSDI, PGA-A, and PGA-D scores at baseline, no significant correlation was found. Comparison of the subgroups according to the initial mLoSSI and LoSDI scores revealed no significant histopathological differences between the groups. Conclusion: Although the mLoSSI, LoSDI, PGA-A, and PGA-D scores can be successfully used for the follow-up and treatment of patients with morphea, no correlation was found between positive ANA, high levels of thyroid autoantibodies, and histopathological features. autoimmune diseases, clinical symptoms, and concomitant lichen sclerosus et atrophicus (LSA) were recorded. Laboratory results, detailed treatment modalities, treatment duration, and treatment responses were assessed. The same dermatologist performed a biopsy of the erythematous rim of the inflammatory lesions or central sclerosis of the lesions that did not clinically show inflammation using a 4 mm punch biopsy instrument. Incisional biopsy was performed in patients with a provisional diagnosis of linear morphea, deep type morphea, or eosinophilic fasciitis.","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43467637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of COVID-19 risk in patients on systemic retinoid therapy 系统性视黄醇治疗患者新冠肺炎风险评估
Q4 Medicine Pub Date : 2022-09-30 DOI: 10.4274/turkderm.galenos.2022.90132
E. Acar, Kemal Özyurt, R. Akyol
Background and Design: Systemic retinoids are commonly used medications in dermatology and indicated in various skin disorders such as acne vulgaris and psoriasis. Data about the risk of Coronavirus disease-2019 (COVID-19) in patients using systemic retinoids are limited. Thus, this study aimed to investigate the risk of COVID-19 in patients undergoing systemic retinoid therapy. Materials and Methods: A total of 186 patients who have undergone systemic isotretinoin and acitretin therapy were recruited. Patients who presented to the dermatology clinic for various skin diseases, such as eczema, vitiligo, tinea, etc., who were not on systemic retinoid therapy, and who received topical medications comprised the control group. The development of COVID-19 in the retinoid therapy group and the control group was retrospectively reviewed using hospital database. Results: The mean age of the patients in the retinoid therapy group was 25.72 +/- 0.67 and that in the control group was 25.4 +/- 0.62. Moreover,165 patients received isotretinoin, and 21 patients received acitretin treatment. The isotretinoin dosage ranged from 0.5 to 0.8 mg/kg wheras the acitretin dosage ranged between 10 and 25 mg/day. Two patients (1.07%) in the retinoid therapy group and 8 (4.3%) patients in the control group were diagnosed with COVID-19. None of the patients receiving acitretin was diagnosed with COVID-19. COVID-19 diagnosis was established in the 2nd and 3rd months of isotretinoin treatment, and lung involvement was not observed. No significant difference regarding the number of COVID-19 cases and disease severity was found between the two groups (p=0.105;p=0.258, respectively). Conclusion: Isotretinoin and acitretin use was not associated with increased COVID-19 risk or disease severity. Systemic retinoids appear to be a safe treatment modality in the COVID-19 era.
背景和设计:系统性类视黄醇是皮肤科常用的药物,适用于各种皮肤疾病,如寻常痤疮和银屑病。关于使用系统性类视黄醇的患者患2019冠状病毒病(新冠肺炎)风险的数据有限。因此,本研究旨在调查接受全身类视黄醇治疗的患者患新冠肺炎的风险。材料和方法:共招募186名接受全身异维甲酸和阿曲汀治疗的患者。因各种皮肤病(如湿疹、白癜风、癣等)到皮肤科诊所就诊的患者,未接受全身类视黄醇治疗的患者,以及接受局部药物治疗的患者构成对照组。使用医院数据库回顾性回顾了类视黄醇治疗组和对照组的新冠肺炎发展情况。结果:类视黄醇治疗组患者的平均年龄为25.72±0.67,对照组为25.4±0.62。此外,165名患者接受异维甲酸治疗,21名患者接受阿曲汀治疗。异维甲酸的剂量范围为0.5至0.8 mg/kg风团,阿曲汀的剂量范围在10至25 mg/天之间。视黄醇治疗组的2名患者(1.07%)和对照组的8名患者(4.3%)被诊断为新冠肺炎。接受阿曲汀治疗的患者均未被诊断为新冠肺炎。新冠肺炎诊断在异维甲酸治疗的第2个月和第3个月确定,未观察到肺部受累。在新冠肺炎病例数和疾病严重程度方面,两组之间没有发现显著差异(分别为p=0.105;p=0.258)。结论:异维甲酸和阿曲汀的使用与新冠肺炎风险或疾病严重程度的增加无关。在新冠肺炎时代,系统性类视黄醇似乎是一种安全的治疗方式。
{"title":"Evaluation of COVID-19 risk in patients on systemic retinoid therapy","authors":"E. Acar, Kemal Özyurt, R. Akyol","doi":"10.4274/turkderm.galenos.2022.90132","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2022.90132","url":null,"abstract":"Background and Design: Systemic retinoids are commonly used medications in dermatology and indicated in various skin disorders such as acne vulgaris and psoriasis. Data about the risk of Coronavirus disease-2019 (COVID-19) in patients using systemic retinoids are limited. Thus, this study aimed to investigate the risk of COVID-19 in patients undergoing systemic retinoid therapy. Materials and Methods: A total of 186 patients who have undergone systemic isotretinoin and acitretin therapy were recruited. Patients who presented to the dermatology clinic for various skin diseases, such as eczema, vitiligo, tinea, etc., who were not on systemic retinoid therapy, and who received topical medications comprised the control group. The development of COVID-19 in the retinoid therapy group and the control group was retrospectively reviewed using hospital database. Results: The mean age of the patients in the retinoid therapy group was 25.72 +/- 0.67 and that in the control group was 25.4 +/- 0.62. Moreover,165 patients received isotretinoin, and 21 patients received acitretin treatment. The isotretinoin dosage ranged from 0.5 to 0.8 mg/kg wheras the acitretin dosage ranged between 10 and 25 mg/day. Two patients (1.07%) in the retinoid therapy group and 8 (4.3%) patients in the control group were diagnosed with COVID-19. None of the patients receiving acitretin was diagnosed with COVID-19. COVID-19 diagnosis was established in the 2nd and 3rd months of isotretinoin treatment, and lung involvement was not observed. No significant difference regarding the number of COVID-19 cases and disease severity was found between the two groups (p=0.105;p=0.258, respectively). Conclusion: Isotretinoin and acitretin use was not associated with increased COVID-19 risk or disease severity. Systemic retinoids appear to be a safe treatment modality in the COVID-19 era.","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47728377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trichofolliculoma on gluteal area: A unique case report 臀区毛滤泡瘤:一独特病例报告
Q4 Medicine Pub Date : 2022-09-30 DOI: 10.4274/turkderm.galenos.2022.12499
S. Taşan, C. Tataroğlu, E. Savk, Fatma Nalbant
A unique Abstract Trichofolliculoma is a rare benign cystic nodule, consisting of a central dilated hair follicle that radiates into the surrounding dermis. Trichofolliculoma presents as a dome-shaped, solitary, 0.5-1.0 cm diameter of papule or nodule with a central pore. The clinical differential diagnosis of trichofolliculoma includes basal cell carcinoma, milia, keratoacanthoma, trichoepithelioma, and syringoma. Histopathological differential diagnosis includes trichoepithelioma, dilated pore of Winer, pilar sheath acanthoma, and basal cell carcinoma. Trichofollicumas usually occur on the face and less frequently on the neck and scalp. The gluteal area is an unprecedented site for trichofolliculoma although some unusual locations were observed. Herein, we report a very rare trichofolliculoma of the gluteal area which was not reported in English literature. gluteal
摘要毛囊瘤是一种罕见的良性囊性结节,由中央扩张的毛囊放射到周围真皮。毛囊瘤呈圆顶状,单生,直径0.5-1.0 cm的丘疹或结节,中心有孔。毛毛囊瘤的临床鉴别诊断包括基底细胞癌、粟粒瘤、角棘瘤、毛上皮瘤和注射器瘤。组织病理学鉴别诊断包括毛上皮瘤、维纳氏孔扩张、柱鞘棘球瘤和基底细胞癌。毛囊瘤通常出现在脸上,很少出现在颈部和头皮上。臀区是一个前所未有的部位,虽然一些不寻常的位置观察。在此,我们报告一个非常罕见的毛囊瘤的臀区,这是没有报道在英文文献。臀
{"title":"Trichofolliculoma on gluteal area: A unique case report","authors":"S. Taşan, C. Tataroğlu, E. Savk, Fatma Nalbant","doi":"10.4274/turkderm.galenos.2022.12499","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2022.12499","url":null,"abstract":"A unique Abstract Trichofolliculoma is a rare benign cystic nodule, consisting of a central dilated hair follicle that radiates into the surrounding dermis. Trichofolliculoma presents as a dome-shaped, solitary, 0.5-1.0 cm diameter of papule or nodule with a central pore. The clinical differential diagnosis of trichofolliculoma includes basal cell carcinoma, milia, keratoacanthoma, trichoepithelioma, and syringoma. Histopathological differential diagnosis includes trichoepithelioma, dilated pore of Winer, pilar sheath acanthoma, and basal cell carcinoma. Trichofollicumas usually occur on the face and less frequently on the neck and scalp. The gluteal area is an unprecedented site for trichofolliculoma although some unusual locations were observed. Herein, we report a very rare trichofolliculoma of the gluteal area which was not reported in English literature. gluteal","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45873217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Eccrine chromhidrosis in severe acute respiratory syndromecoronavirus- 2 virus infection treated with favipiravir 法匹拉韦治疗严重急性呼吸系统综合征患者的汗腺多汗症冠状病毒2型感染
Q4 Medicine Pub Date : 2022-09-30 DOI: 10.4274/turkderm.galenos.2022.11455
Müge Göre Karaali, G. Issın, Soner Karaali, Şevki Özdemir
Coronavirus disease-2019 (COVID-19) caused by the severe acute respiratory syndrome-coronavirus-2, which became a pandemic, may have cutaneous findings. Eccrine chromhidrosis is a rare disorder characterized by the excretion of colored sweat via the eccrine sweat glands. We present eccrine chromhidrosis in two COVID-19 cases treated with favipiravir.
2019冠状病毒病(新冠肺炎)由严重急性呼吸综合征冠状病毒2引起,并成为一种流行病,可能有皮肤发现。汗腺汗汗汗症是一种罕见的疾病,其特征是通过汗腺排出有色汗液。我们报道了两例接受法匹拉韦治疗的新冠肺炎患者的小汗腺汗汗腺。
{"title":"Eccrine chromhidrosis in severe acute respiratory syndromecoronavirus- 2 virus infection treated with favipiravir","authors":"Müge Göre Karaali, G. Issın, Soner Karaali, Şevki Özdemir","doi":"10.4274/turkderm.galenos.2022.11455","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2022.11455","url":null,"abstract":"Coronavirus disease-2019 (COVID-19) caused by the severe acute respiratory syndrome-coronavirus-2, which became a pandemic, may have cutaneous findings. Eccrine chromhidrosis is a rare disorder characterized by the excretion of colored sweat via the eccrine sweat glands. We present eccrine chromhidrosis in two COVID-19 cases treated with favipiravir.","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46532938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of the efficacy of microneedling combined with 5-fluorouracil 5% cream versus microneedling combined with tacrolimus 0.1% ointment in the treatment of vitiligo 微针联合5% 5-氟尿嘧啶乳膏与微针联合0.1%他克莫司软膏治疗白癜风的疗效比较
Q4 Medicine Pub Date : 2022-06-30 DOI: 10.4274/turkderm.galenos.2022.57804
Parwaaz Matharoo, Saurabh Sharma, Jasleen Kaur, R. Bassi
{"title":"Comparison of the efficacy of microneedling combined with 5-fluorouracil 5% cream versus microneedling combined with tacrolimus 0.1% ointment in the treatment of vitiligo","authors":"Parwaaz Matharoo, Saurabh Sharma, Jasleen Kaur, R. Bassi","doi":"10.4274/turkderm.galenos.2022.57804","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2022.57804","url":null,"abstract":"","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48665904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What is your diagnosis? 你的诊断是什么?
Q4 Medicine Pub Date : 2022-06-30 DOI: 10.4274/turkderm.galenos.2022.14412
R. Ottevanger, R. Genders
{"title":"What is your diagnosis?","authors":"R. Ottevanger, R. Genders","doi":"10.4274/turkderm.galenos.2022.14412","DOIUrl":"https://doi.org/10.4274/turkderm.galenos.2022.14412","url":null,"abstract":"","PeriodicalId":49412,"journal":{"name":"Turkderm-Archives of the Turkish Dermatology and Venerology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41567836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Turkderm-Archives of the Turkish Dermatology and Venerology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1